Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NFBK
651
DELISTED
Northfield Bancorp
NFBK
| $27.6M | 0.02% |
2,394,887
-58,450
| -2% | -$635K |
2013 Q2
28 quarters
|
|
652
First American
FAF
$6.25B
| $27.5M | 0.02% |
573,166
+336,323
| +142% | +$15.9M |
2016 Q1
17 quarters
|
|
|
WBK
653
DELISTED
Westpac Banking Corporation
WBK
| $27.5M | 0.02% |
2,197,660
-552,600
| -20% | -$6.06M |
2014 Q3
23 quarters
|
|
|
QADA
654
DELISTED
QAD Inc.
QADA
| $27.4M | 0.02% |
663,977
+43,200
| +7% | +$1.82M |
2013 Q2
28 quarters
|
|
655
Federal Realty Investment Trust
FRT
$9.22B
| $27.3M | 0.02% |
320,600
+70,198
| +28% | +$5.67M |
2016 Q4
14 quarters
|
|
656
Cohu
COHU
$3.23B
| $27.3M | 0.02% |
1,572,517
-167,200
| -10% | -$2.58M |
2014 Q3
23 quarters
|
|
|
EBSB
657
DELISTED
Meridian Bancorp, Inc.
EBSB
| $27.2M | 0.02% |
2,343,859
-141,000
| -6% | -$1.57M |
2013 Q2
28 quarters
|
|
|
SPNS
658
DELISTED
Sapiens International
SPNS
| $27.2M | 0.02% |
971,503
+47,100
| +5% | +$1.15M |
2013 Q2
28 quarters
|
|
659
Xerox
XRX
$361M
| $27.1M | 0.02% |
1,772,785
+468,902
| +36% | +$8.09M |
2019 Q4
2 quarters
|
|
|
CERN
660
DELISTED
Cerner Corp
CERN
| $27.1M | 0.02% |
395,404
-46,000
| -10% | -$3.16M |
2019 Q3
3 quarters
|
|
661
CRISPR Therapeutics
CRSP
$5.16B
| $27.1M | 0.02% |
368,658
-140,517
| -28% | -$8.22M |
2019 Q3
3 quarters
|
|
662
Halozyme
HALO
$12.5B
| $27M | 0.02% |
1,008,200
+684,800
| +212% | +$15.4M |
2019 Q4
2 quarters
|
|
663
Zimmer Biomet
ZBH
$17B
| $27M | 0.02% |
233,192
-291,902
| -56% | -$33.6M |
2020 Q1
1 quarter
|
|
664
Bruker
BRKR
$8.96B
| $27M | 0.02% |
663,710
+213,400
| +47% | +$8.4M |
2020 Q1
1 quarter
|
|
|
CIO
665
DELISTED
City Office REIT
CIO
| $26.8M | 0.02% |
2,660,903
-757,894
| -22% | -$7.01M |
2015 Q1
21 quarters
|
|
666
Bank of Hawaii
BOH
$2.64B
| $26.8M | 0.02% |
435,600
-190,700
| -30% | -$11.8M |
2017 Q1
13 quarters
|
|
|
BMCH
667
DELISTED
BMC Stock Holdings, Inc
BMCH
| $26.7M | 0.02% |
1,060,849
-294,800
| -22% | -$6.52M |
2018 Q3
7 quarters
|
|
668
Zymeworks
ZYME
$1.85B
| $26.7M | 0.02% |
739,134
-60,613
| -8% | -$2.23M |
2018 Q2
8 quarters
|
|
669
NOV
NOV
$6.76B
| $26.6M | 0.02% |
2,172,610
+788,300
| +57% | +$9.69M |
2020 Q1
1 quarter
|
|
670
Stryker
SYK
$106B
| $26.5M | 0.02% |
147,300
+115,900
| +369% | +$21.4M |
2019 Q4
2 quarters
|
|
|
AMRN
671
Amarin Corp
AMRN
$254M
| $26.4M | 0.02% |
190,663
+72,463
| +61% | +$9.97M |
2020 Q1
1 quarter
|
|
672
Watts Water Technologies
WTS
$11.8B
| $26.3M | 0.02% |
324,790
-94,100
| -22% | -$7.58M |
2015 Q1
21 quarters
|
|
673
Safety Insurance
SAFT
$1.52B
| $26.3M | 0.02% |
344,900
+5,300
| +2% | +$415K |
2014 Q2
24 quarters
|
|
|
LSI
674
DELISTED
Life Storage, Inc.
LSI
| $26.2M | 0.02% |
414,600
-444,750
| -52% | -$27.6M |
2018 Q1
9 quarters
|
|
675
Telefônica Brasil
VIV
$19.5B
| $26.2M | 0.02% |
2,958,849
+950,796
| +47% | +$8.62M |
2017 Q2
12 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.